Amfexa is NOT Lisdexamfetamine
Amfexa and lisdexamfetamine (lisdexamfetamine dimesylate) are completely different medications with distinct chemical structures, mechanisms of action, and pharmacokinetic profiles.
Chemical and Pharmacological Differences
Lisdexamfetamine dimesylate is a prodrug consisting of dextroamphetamine covalently bound to the amino acid lysine 1. The chemical designation is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate, with molecular formula C15H25N3O∙(CH4O3S)2 and molecular weight of 455.60 1.
The prodrug remains pharmacologically inactive until enzymatic cleavage (predominantly by red blood cells) converts it to active d-amphetamine and lysine 2, 3. This conversion results in:
- Tmax for lisdexamfetamine: approximately 1-1.5 hours, with rapid decline (negligible levels by 6 hours) 3
- Tmax for d-amphetamine (after conversion): approximately 3.5-4.4 hours post-dose 1, 3
- Duration of clinical effects: up to 14 hours 2, 3
Regulatory Status and Approved Indications
Lisdexamfetamine dimesylate is approved for 1:
- Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients
- Moderate-to-severe Binge Eating Disorder (BED) in adults
It is classified as a Schedule II controlled substance due to high potential for abuse and dependence 1.
Geographic Availability
According to international guidelines, lisdexamfetamine dimesylate (referred to as LDX) is available in specific countries with varying regulatory positions 4, 5:
- Japan: Approved as third-line treatment for ADHD after OROS-MPH, atomoxetine, and guanfacine 4
- United States: Approved as first-line therapy 5
- European countries: Approved as second-line therapy in many jurisdictions 5
- Not mentioned as available in China, Taiwan, or Indonesia in the Asian guidelines review 4
Critical Distinction
If "Amfexa" refers to a different formulation or brand name, it would need to be verified against official drug databases. However, based on FDA labeling and international guidelines, the only recognized formulation of lisdexamfetamine is lisdexamfetamine dimesylate, available in capsule strengths of 10,20,30,40,50,60, and 70 mg 1.
Any medication claiming to be lisdexamfetamine must contain lisdexamfetamine dimesylate as the active pharmaceutical ingredient with the exact chemical structure specified above. Different brand names may exist across countries, but the active ingredient remains identical.